119 results on '"Lee, Samuel"'
Search Results
2. PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice
3. PAR4 Inhibition Reduces Coronary Artery Atherosclerosis and Myocardial Fibrosis in SR-B1/LDLR Double Knockout Mice
4. Joint Modeling of Clinical and Biomarker Data in Acute Kidney Injury Defines Unique Subphenotypes with Differing Outcomes
5. Joint Modeling of Clinical and Biomarker Data in Acute Kidney Injury Defines Unique Subphenotypes with Differing Outcomes
6. Ocular neuromyotonia: a review of diagnosis and treatment
7. HBV-related acute-on-chronic liver failure with underlying chronic hepatitis has superior survival compared to cirrhosis
8. HBV-related acute-on-chronic liver failure with underlying chronic hepatitis has superior survival compared to cirrhosis
9. Treatment of Horizontal Binocular Diplopia With Prismatic Contact Lenses
10. URINARY BETA-2-MICROGLOBULIN AS A BIOMARKER FOR CHRONIC ALLOGRAFT INJURY AND RAPID RENAL FUNCTION DECLINE IN KIDNEY TRANSPLANT RECIPIENTS
11. DEVELOPMENT OF WEB-BASED E-LEARNING EDUCATIONAL CONTENTS FOR ORGAN DONATION AND TRANSPLANTATION TOWARD MEDICAL STUDENTS AND MEDICAL PERSONNEL
12. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
13. Fourth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting
14. The AHAʼS 7 Health Metrics And Chronic Disease Mortality In Patients With CHD, Stroke, And Cancer: 1608 Board #202 May 28 10:30 AM - 12:00 PM
15. Understanding and managing cardiovascular outcomes in liver transplant recipients
16. β-Blocker therapy for cirrhotic cardiomyopathy: a randomized-controlled trial
17. Metformin and AMP Kinase Activation Increase Expression of the Sterol Transporters ABCG5/8 (ATP-Binding Cassette Transporter G5/G8) With Potential Antiatherogenic Consequences
18. Identification of Urinary Biomarkers for Recurrence of IgA Nephropathy After Kidney Transplantation Using Proteomic Methods
19. Lung Abscess Due to Aspergillus lentulus and Pseudomonas aeruginosa in a Patient With Granulomatosis With Polyangiitis: Case and Review of the Literature
20. FES-assisted Cycling Improves Aerobic Capacity and Locomotor Function Postcerebrovascular Accident
21. Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial
22. Medical research and audit skills training for undergraduates: an international analysis and student-focused needs assessment
23. Clinical and subjective evaluation of implants in patients with hypodontia: a two‐year observation study
24. Does Opioid Use Cause Angiogenesis and Metastasis?
25. The need for histological subclassification of cirrhosis: a systematic review and meta-analysis
26. EuroSurg: a new European student-driven research network in surgery
27. New paradigms in hepatitis B management: only diamonds are forever
28. Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
29. Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection
30. Diagnosis and management of acute kidney injury in patients with cirrhosis: revised consensus recommendations of the International Club of Ascites
31. Revolution in hepatitis C antiviral therapy
32. TURQUOISE-II: Regimens of ABT-450/r/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients with Cirrhosis, Regardless of Baseline Characteristics: 81
33. Thioredoxin-interacting protein regulates protein disulfide isomerases and endoplasmic reticulum stress
34. Cranberry-derived proanthocyanidins prevent formation of Candida albicans biofilms in artificial urine through biofilm- and adherence-specific mechanisms
35. Motor and sensory neuropathy due to myelin infolding and paranodal damage in a transgenic mouse model of Charcot–Marie–Tooth disease type 1C
36. How to optimize HCV therapy in genotype 1 patients: management of side-effects
37. Gens Una Sumus – still
38. Ribavirin dose reduction versus erythropoietin for anemia management in previously untreated patients with chronic hepatitis C receiving boceprevir plus peginterferon/ribavirin: FP03–02
39. Journalsʼ impact and pecking order: tyranny and tyrannosaurs
40. PPARα activation in portal hypertension
41. A randomized trial comparing ribavirin dose reduction versus erythropoietin for anaemia management in previously untreated patients with chronic hepatitis c receiving boceprevir plus peginterferon/ribavirin
42. Hyperdynamic Circulation In Portal Hypertensive Rats is Initiated by Mesenteric Oxidative Stress: 1148
43. Twelve- or 16-Week Treatment With Daclatasvir Combined With Peginterferon Alfa and Ribavirin for Hepatitis C Virus Genotype 2 or 3 Infection: Command GT2/3 Study: 762
44. Six Weeks of a NS5A Inhibitor (GS-5885), Protease Inhibitor (GS-9451) plus Peginterferon/Ribavirin (PR) Achieves High SVR4 Rates in Genotype 1 IL28B CC Treatment Naïve HCV Patients: Interim Results of a Prospective, Randomized Trial: 759
45. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients
46. The spleen is a player in portal hypertension
47. Therapeutic implications of protein homeostasis in demyelinating peripheral neuropathies
48. Dealing with editors: ‘nice n’ easy does it every time’
49. Prevalence and Mechanisms of Malnutrition in Patients With Advanced Liver Disease, and Nutrition Management Strategies
50. Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.